Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. (NASDAQ: SNES) generates news as a biotechnology company focused on fertility control for rodent management. Its announcements frequently highlight developments related to ContraPest®, Evolve Rat, and Evolve Mouse Birth Control, which are described as contraceptive products for rats and mice that fit into integrated pest management programs and reduce reliance on traditional rodenticides.
Investors and observers following SNES news will see regular updates on financial performance and growth in Evolve rodent birth control products. Quarterly press releases report record revenues, gross profit margins, and the share of revenue contributed by Evolve-branded products, as well as commentary on adjusted EBITDA and cash balances. These releases often discuss progress toward profitability and the impact of multi-channel distribution strategies.
Company news also covers operational and commercial milestones. Examples include the launch of Evolve Rat Birth Control on major e-commerce platforms and home improvement retailer websites, expanded retail coverage through partners and wholesalers, and municipal pilot deployments in U.S. cities. Additional updates describe international distribution relationships, such as the appointment of the Belize Raptor Center as an official distributor following regulatory approval in Belize.
Regulatory and capital markets activities appear in SenesTech’s news flow as well. The company issues press releases on warrant exercises, gross proceeds from financings, and participation in investor conferences. For readers tracking SNES, this news page offers a way to monitor how SenesTech reports on product adoption, distribution channels, municipal and community programs, and financing events over time.
SenesTech, Inc. (NASDAQ: SNES) announced the deployment of its rodent fertility control product, ContraPest®, at Safari West Wildlife Preserve in California. This initiative is part of a broader eco-friendly pest management strategy, crucial for controlling rat populations that can rapidly reproduce in safe environments. ContraPest offers a non-lethal solution that has proven to reduce rat populations by at least 94%. The product is now increasingly being adopted in zoos and sanctuaries across the U.S., with expectations of continued growth in this market.
SenesTech (NASDAQ: SNES) announced that Columbus, Ohio has integrated ContraPest® into its pest management program, joining other cities like San Francisco and Washington D.C. This environmentally friendly solution has achieved up to a 94% reduction in urban rat populations. Columbus enhances its free residential pest management services with ContraPest, focusing on eco-friendly approaches. CEO Ken Siegel noted the growing acceptance of fertility control methods in pest management, especially after California's ban on certain rodenticides. The company aims for further expansion into other municipalities.
SenesTech (SNES) announced that Los Angeles County will require fertility control in pest management proposals for 2022. This mandate highlights the importance of SenesTech's product, ContraPest®, the only EPA registered rodent fertility control solution. ContraPest® can reduce rat populations by up to 94% when integrated into pest management programs. Following California's legislation banning certain rodenticides, demand for humane pest control alternatives is expected to grow, with other municipalities adopting ContraPest® as well.
SenesTech, a leader in animal pest management through fertility control, will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021. The company will host a webcasted Fireside Chat on December 13 at 11:00am ET, discussing its 2022 vision. Investors can view the webcast on the company's website or via a specific link. Additionally, 1x1 virtual meetings with management can be arranged through Lytham Partners. SenesTech focuses on rodent fertility control, aiming to reduce pest populations and promote a healthier environment.
SenesTech (NASDAQ: SNES) reported that Q3 2021 revenues exceeded $183,000, more than doubling from $77,000 in Q3 2020. Year-to-date revenues also more than doubled, driven by growth in agribusiness, municipalities, and direct-to-consumer markets. The company added around 350 new customers, with California sales accounting for nearly 30% of total sales. Despite revenue growth, Q3 net loss widened to $(2.3) million from $(1.9) million in Q3 2020. As of September, the company had $11.1 million in cash to support further growth initiatives.
SenesTech, Inc. (NASDAQ: SNES) will report its financial results for Q3 2021 after market close on November 10, 2021. A conference call is scheduled for the same day at 5:00 pm ET to discuss the results. SenesTech focuses on managing pest populations through its proprietary fertility control technology, ContraPest®, which is the first EPA registered rodent contraceptive. This initiative aims to significantly reduce rodent populations and promote a healthier environment.
SenesTech (NASDAQ: SNES) has seen municipalities across the U.S. increasingly adopt its rat contraceptive, ContraPest®, with Newton, Massachusetts, now joining cities like Washington DC and San Francisco. ContraPest® is the only EPA-approved rat birth control, demonstrating over 94% efficacy in reducing rat populations. Sales revenues for ContraPest® soared over 100% in 2021, primarily driven by California's implementation of rodenticide restrictions. This innovative solution addresses the growing rat problem exacerbated by the pandemic, aiming for sustainable pest control without harmful impacts.
SenesTech, Inc. (NASDAQ: SNES) has announced its participation in the Lytham Partners Fall 2021 Investor Conference on October 7, 2021 at 3:30 PM ET. The event will be accessible via a webcast on the company's website, with an archived replay available post-event. Management will also hold virtual one-on-one meetings during the conference from October 5 to 7. As a leader in fertility control technology for pest management, SenesTech aims to promote a healthier environment through its proprietary product, ContraPest, the first U.S. EPA registered rodent contraceptive.
SenesTech, Inc. (NASDAQ: SNES) reported a 125% revenue increase in Q2 2021 compared to Q2 2020, totaling $160,000. Year-to-date revenues rose 130%. Growth is fueled by the adoption of ContraPest, especially in California, following legislation limiting anticoagulant rodenticides. The company engages nearly 500 active customers, with 250 new additions in Q2. Despite a net loss of $(1.7) million, cash reserves stand at $13.1 million. An aggressive marketing campaign, "Operation Rat Race," is set to further boost sales.
SenesTech, Inc. (NASDAQ: SNES) will report its second quarter 2021 financial results on August 12, 2021, after market close. The company specializes in fertility control technologies for managing animal pest populations, particularly rats, through its proprietary product, ContraPest. A conference call to discuss the results is scheduled for 5:00 pm ET on the same day, accessible via phone or live webcast. Interested parties can engage in the call through specified dial-in numbers or the investor relations section of their website.